Orphazyme: Surges before FDA decision on genetic disorder drug

Strategic Partners A/S

16/06/2021 18:15

** U.S.-listed shares of drug developer  ORPH.O  surge ~91%
to $19.16
    ** U.S. FDA set to decide on whether to approve company's
lead candidate, arimoclomol, to treat Niemann-Pick Disease Type
C (NPC)
    ** NPC is a rare genetic disorder leading to abnormal
accumulation of cholestrol and lipids within various tissues of
the body
    ** FDA had extended drug's review period by three months in
December and set target action date of June 17  urn:newsml:reuters.com:*:nL4N2J823R
    ** Including session's gain, stock up ~80% YTD

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))